Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021; 23(7):E563-568. doi:
10.1001/amajethics.2021.563.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021; 23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Elizabeth Boskey, PhD, MPH, MSSW, Amir Taghinia, MD, and Oren Ganor, MD
Training should be implemented to respond to clinical staff members’ concerns about trans patients occupying sex-segregated spaces and to help mitigate anti-trans bias.
AMA J Ethics. 2018; 20(11):E1067-1074. doi:
10.1001/amajethics.2018.1067.